OneSource Specialty Pharma Ltd Q1 FY26: A ₹21,000 Cr Unicorn with P/E Higher than Your Heart Rate and Margins Juicier than a Mysore Dosa
1. At a Glance
OneSource Specialty Pharma (OSSPL), the freshly carved-out biotech CDMO from the Strides Pharma family, is the latest market darling: ₹21,300 Cr market cap, ₹1,480 Cr sales, and an eye-watering P/E of 238. Margins? A fat 33%. Profits? ₹89 Cr for FY25 but only ₹2.5 Cr this quarter. Promoters? Reducing stake like you reduce sugar after diabetes diagnosis—down from 38% to 30%, with 25% pledged. Investors? Still drooling like it’s the next Biocon.
2. Introduction
There are IPO fads, there are demerger dramas, and then there is OneSource Specialty Pharma Ltd—a biotech CDMO trying to convince Dalal Street it’s the “next Lonza” while still figuring out how to balance profit vs. promises.
Born in 2023 from Strides’ surgical corporate restructuring, OSSPL inherited sterile injectables, soft gels, and biologics capacity—basically all the high-science, high-margin businesses that sound fancy in investor decks. By 2024, it was rebranded, given a sleek logo, and thrown into the markets with biotech buzzwords like “biosimilars,” “drug-device combos,” and “end-to-end CDMO” pasted all over its pitchbook.
And the Street bought it—literally. The stock shot up to ₹2,250 before cooling to ₹1,860. But scratch the glossy surface: ROE is a thin 3.3%, interest coverage barely 1.5x, debtor days stretched to 105, and promoters quietly selling down their stake.
So here’s the real story: OSSPL is the kind of company that can announce a biosimilar tie-up in June, a Brazilian GMP approval in April, and a USFDA inspection in March—all while posting near-zero net profit in June. Glamorous? Yes. Sustainable? Well… let’s investigate.
3. Business Model – WTF Do They Even Do?
If you’re confused, don’t worry—even the pharma analysts nod politely in presentations and Google later. OSSPL is a CDMO (Contract Development & Manufacturing Organisation). In simpler desi terms:
Think of them as the wedding caterer of pharma. Big pharma companies (Sun, Pfizer, or some Swedish biotech startup with four employees and big dreams) outsource part of their drug R&D, trials, or manufacturing to OSSPL. OneSource then does all the heavy lifting: develop biologics, scale up batches, clear regulatory approvals, and ship injectables worldwide.
Their verticals are like the “menu card”:
Biologics (biosimilars, monoclonal antibodies, peptides) – the five-star dishes.
Soft Gelatin Capsules – the comfort food.
Drug-device combos (like inhalers, auto-injectors) – the “fusion cuisine” that everyone claims to love but no one actually orders.
Revenue comes from contract manufacturing & development fees (~98%). Scrap sales and interest income are rounding errors, just there to remind you Excel sheets need totals.
Facilities? Two massive units in Karnataka, EU-GMP and USFDA approved, churning out up to 400 million drug units annually. Basically, enough injectables to jab every citizen of Europe and still have leftovers for Africa.
